Eli Lilly (LLY) Minority Interest (2009 - 2025)

Eli Lilly has reported Minority Interest for 17 years, with the latest figure at $57.5 million in Q3 2025.

• For the quarter ending Q3 2025, Minority Interest fell 28.75% year-over-year to $57.5 million; the trailing twelve-month figure through Sep 2025 stood at $57.5 million (down 28.75% YoY), and the FY2024 full-year result was $79.5 million, down 13.4% from the prior year.
• Minority Interest for Q3 2025 stood at $57.5 million, down from $76.2 million in the prior quarter.
• The five-year high for Minority Interest was $219.1 million in Q2 2021, with the low at $57.5 million in Q3 2025.
• Historically, Minority Interest has averaged $113.8 million across 5 years, with a median of $91.8 million in 2023.
• Annual changes were most pronounced in 2021 — Minority Interest jumped 69.43% — and 2022, when it sank 51.4%.
• Eli Lilly's Minority Interest stood at $175.6 million in 2021, then fell by 28.47% to $125.6 million in 2022, then decreased by 26.91% to $91.8 million in 2023, then retreated by 13.4% to $79.5 million in 2024, then slipped by 27.67% to $57.5 million in 2025.
• The last three Minority Interest figures came in at $57.5 million (Q3 2025), $76.2 million (Q2 2025), and $82.0 million (Q1 2025), per Business Quant data.